flutamide has been researched along with Androgen-Independent Prostatic Cancer in 24 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Men with nonmetastatic prostate cancer were treated with 9 months of leuprolide and flutamide followed by a variable off-treatment interval; AD was resumed when prostate specific antigen (PSA) reached a prespecified value (1 ng/mL, radical prostatectomy; 4 ng/mL, intact prostate)." | 2.80 | Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. ( Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Hunter-Merrill, R; Kuo, KF; Yu, EY, 2015) |
| "In contrast, in androgen-independent prostate cancer cell lines, TROP2high cells did not exhibit a differential treatment response but were characterized by their high self-renewal ability." | 1.43 | High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells. ( Butler, L; Hollande, F; Mølck, C; Paquet-Fifield, S; Sloan, E; Ventura, S; Xie, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (66.67) | 24.3611 |
| 2020's | 8 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, S | 1 |
| Oguri, H | 1 |
| Segawa, J | 1 |
| Kawai, M | 1 |
| Hu, D | 1 |
| Xia, S | 2 |
| Okada, T | 1 |
| Irie, K | 1 |
| Fujii, S | 2 |
| Gouda, H | 1 |
| Iguchi, K | 1 |
| Matsukawa, T | 1 |
| Fujimoto, N | 1 |
| Nakayama, T | 1 |
| Toyooka, N | 1 |
| Matsunaga, T | 1 |
| Ikari, A | 1 |
| Uemura, H | 1 |
| Kobayashi, K | 2 |
| Yokomizo, A | 1 |
| Hinotsu, S | 1 |
| Horie, S | 1 |
| Kakehi, Y | 1 |
| Nonomura, N | 1 |
| Ogawa, O | 2 |
| Oya, M | 1 |
| Suzuki, K | 1 |
| Saito, A | 1 |
| Asakawa, K | 1 |
| Uno, S | 1 |
| Naito, S | 1 |
| Wang, H | 3 |
| Wei, X | 3 |
| Zhang, D | 3 |
| Li, W | 3 |
| Hu, Y | 3 |
| Madan, RA | 1 |
| Bilusic, M | 1 |
| Stein, MN | 1 |
| Donahue, RN | 1 |
| Arlen, PM | 1 |
| Karzai, F | 1 |
| Plimack, E | 1 |
| Wong, YN | 1 |
| Geynisman, DM | 1 |
| Zibelman, M | 1 |
| Mayer, T | 1 |
| Strauss, J | 1 |
| Chen, G | 1 |
| Rauckhorst, M | 1 |
| McMahon, S | 1 |
| Couvillon, A | 1 |
| Steinberg, S | 1 |
| Figg, WD | 1 |
| Dahut, WL | 1 |
| Schlom, J | 1 |
| Gulley, JL | 1 |
| Fukuoka, K | 1 |
| Teishima, J | 1 |
| Nagamatsu, H | 1 |
| Inoue, S | 1 |
| Hayashi, T | 1 |
| Mita, K | 1 |
| Shigeta, M | 1 |
| Kajiwara, M | 1 |
| Kadonishi, Y | 1 |
| Tacho, T | 1 |
| Matsubara, A | 1 |
| Iguchi, T | 3 |
| Tamada, S | 3 |
| Kato, M | 3 |
| Yasuda, S | 3 |
| Machida, Y | 1 |
| Ohmachi, T | 1 |
| Ishii, K | 1 |
| Iwata, H | 1 |
| Yamamoto, S | 1 |
| Kanamaru, T | 1 |
| Morimoto, K | 1 |
| Hase, T | 1 |
| Tashiro, K | 1 |
| Harimoto, K | 1 |
| Deguchi, T | 1 |
| Adachi, T | 1 |
| Iwamoto, K | 1 |
| Takegaki, Y | 1 |
| Nakatani, T | 3 |
| Kobayashi, T | 1 |
| Terada, N | 1 |
| Kimura, T | 1 |
| Matsubara, N | 1 |
| Murakami, K | 1 |
| Mori, K | 1 |
| Fujimoto, Y | 1 |
| Akamatsu, S | 1 |
| Inoue, T | 2 |
| Muramatsu, T | 1 |
| Funahashi, Y | 1 |
| Yamamoto, A | 1 |
| Sassa, N | 1 |
| Matsukawa, Y | 1 |
| Gotoh, M | 1 |
| Koga, H | 1 |
| Negishi, M | 1 |
| Kinoshita, M | 1 |
| Mori, S | 1 |
| Ishigami-Yuasa, M | 1 |
| Kawachi, E | 1 |
| Kagechika, H | 1 |
| Tanatani, A | 1 |
| Smith, TAD | 1 |
| Phyu, SM | 1 |
| Alzyoud, KS | 1 |
| Tseng, CC | 1 |
| Nakai, Y | 1 |
| Tanaka, N | 2 |
| Miyake, M | 1 |
| Anai, S | 1 |
| Fujimoto, K | 1 |
| Pimenta, RC | 1 |
| Viana, NI | 1 |
| Amaral, GQ | 1 |
| Park, R | 1 |
| Morais, DR | 1 |
| Pontes, J | 1 |
| Guimaraes, VR | 1 |
| Camargo, JA | 1 |
| Leite, KR | 1 |
| Nahas, WC | 1 |
| Srougi, M | 1 |
| Reis, ST | 1 |
| Otoshi, T | 1 |
| Hamada, K | 1 |
| Yamasaki, T | 2 |
| Yamaguchi, N | 1 |
| Morizane, S | 1 |
| Yumioka, T | 1 |
| Iwamoto, H | 1 |
| Hikita, K | 1 |
| Sejima, T | 1 |
| Honda, M | 1 |
| Takenaka, A | 1 |
| Shen, P | 1 |
| Sun, J | 1 |
| Xu, G | 1 |
| Zhang, L | 1 |
| Yang, Z | 1 |
| Wang, Y | 1 |
| Liu, Y | 1 |
| Shi, G | 1 |
| Matsumoto, K | 1 |
| Hagiwara, M | 1 |
| Hayakawa, N | 1 |
| Ito, Y | 1 |
| Maeda, T | 1 |
| Ninomiya, A | 1 |
| Nagata, H | 1 |
| Nakamura, S | 1 |
| Höfner, T | 1 |
| Vallet, S | 1 |
| Hadaschik, BA | 1 |
| Pahernik, S | 1 |
| Duensing, S | 1 |
| Hohenfellner, M | 1 |
| Jäger, D | 1 |
| Grüllich, C | 1 |
| Kuo, KF | 1 |
| Hunter-Merrill, R | 1 |
| Gulati, R | 1 |
| Hall, SP | 1 |
| Gambol, TE | 1 |
| Higano, CS | 1 |
| Yu, EY | 1 |
| Hoang, DT | 1 |
| Gu, L | 1 |
| Liao, Z | 1 |
| Shen, F | 1 |
| Talati, PG | 1 |
| Koptyra, M | 1 |
| Tan, SH | 1 |
| Ellsworth, E | 1 |
| Gupta, S | 1 |
| Montie, H | 1 |
| Dagvadorj, A | 1 |
| Savolainen, S | 1 |
| Leiby, B | 1 |
| Mirtti, T | 1 |
| Merry, DE | 1 |
| Nevalainen, MT | 1 |
| Murray, NP | 1 |
| Reyes, E | 1 |
| Fuentealba, C | 1 |
| Jacob, O | 1 |
| Orellana, N | 1 |
| Lallous, N | 1 |
| Volik, SV | 1 |
| Awrey, S | 1 |
| Leblanc, E | 1 |
| Tse, R | 1 |
| Murillo, J | 1 |
| Singh, K | 1 |
| Azad, AA | 1 |
| Wyatt, AW | 1 |
| LeBihan, S | 1 |
| Chi, KN | 1 |
| Gleave, ME | 1 |
| Rennie, PS | 1 |
| Collins, CC | 1 |
| Cherkasov, A | 1 |
| Xie, J | 1 |
| Mølck, C | 1 |
| Paquet-Fifield, S | 1 |
| Butler, L | 1 |
| Sloan, E | 1 |
| Ventura, S | 1 |
| Hollande, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide.[NCT02346578] | Phase 2 | 104 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| A Prospective Study of Intermittent Androgen Suppression (IAS) in Men With Localized Prostate Cancer Who Have Biochemical Relapse After Radiation Therapy or Radical Prostatectomy[NCT00223665] | Phase 2 | 102 participants (Actual) | Interventional | 1997-01-08 | Completed | ||
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. This measure was defined as the percentage of participants with normal BMD scores at baseline who developed Osteopenia after the first cycle of ADT. (NCT00223665)
Timeframe: From screening prior to first dose of ADT through the start of the second cycle of ADT.
| Intervention | percent of participants (Number) |
|---|---|
| Intermittent Androgen Suppression (IAS) | 13.2 |
Assessment of overall survival measured as median time from completion of first full cycle of IAS until date of death from any cause. (NCT00223665)
Timeframe: From date of first treatment until the date of death or study withdrawal, whichever came first, assessed up to 16 years.
| Intervention | years (Median) |
|---|---|
| Intermittent Androgen Suppression (IAS) | 6.6 |
Monthly Prostate-Specific Antigen (PSA) testing to assess the point at which each patient's disease stops responding to Androgen Deprivation Therapy (ADT). Androgen Independence (AI), also know as Castrate Resistance (CR), was defined as 2 serial rises in PSA while on ADT with Testosterone levels <50 ng/dL. (NCT00223665)
Timeframe: From date of first treatment until the date of development of CR, metastatic progression, or study withdrawal, whichever came first, assessed up to 16 years.
| Intervention | years (Median) |
|---|---|
| Intermittent Androgen Suppression (IAS) | 4.0 |
Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health. Percent change was assess for each patient at each time point. (NCT00223665)
Timeframe: From screening prior to first dose of ADT through the start of the second cycle of ADT.
| Intervention | Percent change of BMD (Number) | |
|---|---|---|
| Post Cycle 1 versus Baseline | Pre Cycle 2 versus Post Cycle 1 | |
| Intermittent Androgen Suppression (IAS) | -1.2 | -0.2 |
Dual-energy x-ray absorptiometry (DEXA) scans were performed prior to first cycle of ADT, after completion of the first cycle of ADT, and prior to the start of the second cycle of ADT. Bone Mineral Density (BMD) was a assessed in g/cm^2 as a indicator of bone health for each patient at each time point. (NCT00223665)
Timeframe: From screening prior to first dose of ADT through the start of the second cycle of ADT.
| Intervention | Percent change in BMD (Number) | |
|---|---|---|
| Post Cycle 1 versus Baseline | Pre Cycle 2 versus Post Cycle 1 | |
| Intermittent Androgen Suppression (IAS) | -3.4 | 1.4 |
Estradiol was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | pg/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Measurement at Month 3 | Measurement at Month 9 | Measurement at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 33.60 | 23.12 | 22.76 | 24.35 |
Executive Function was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Stroop Color Word Interference Task. Subjects are asked to read 100 color words (red, green, blue), followed by identification of color blocks followed by reading the color of the ink and ignoring the word (e.g., the word 'blue' printed in green letters). Assessment was based on the amount of time needed to time to complete the assessment. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | minutes to complete the assessment (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 51.00 | 55.52 | 47.58 | 48.82 |
Spatial Ability was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Wechsler Adult Intelligence Scale-Revised, Block Design sub-test and measures participants' ability to analyze and construct abstract figures from their component parts. The test allows a time limit of 3 minutes per design, for a total of nine designs. Score is based on total number of designs completed (max 9, min 0). (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of correctly completed designs (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Combined Androgen Blockade | 8.65 | 7.20 | 8.82 | 8.47 |
Spatial Ability (Mental Rotation) was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This assessment was based on the Vandenberg & Kuse (1978) Mental Rotation Test. Subjects are presented with line drawings of complex, three dimensional cubes on a computer screen. The subject must compare the two drawings and decide if they match. Score is based on number of correctly identified figures. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of correctly identified figures (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 16.12 | 13.00 | 16.52 | 15.53 |
Spatial Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT using the Puget Sound Route Learning Test. This test measured the ability to navigate a short route within a room. Three trials were administered followed by three trials of a new route using pictures placed on the floor as landmarks. A delayed recall is administered after twenty minutes. Performance was assessed based on number of correctly recalled sequences after a delay. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | number of correctly recalled sequences (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 19.50 | 22.00 | 23.76 | 24.12 |
Verbal Ability/Fluency was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. Participants were asked to verbally generate as many words beginning with a particular letter (e.g. P) within a 60 second period. Two trials were administered with two different letters. The total number of words generated was recorded for each letter and summed and analyzed. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of words generated (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 24.65 | 26.15 | 26.29 | 25.70 |
Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via the Proactive Interference (PI) task. The PI task involves participants listening to a list of 10 words from the same semantic category (e.g., articles of clothing), and then recalling as many of these words as possible.The procedure is repeated for a total of 4 trials. Assessment is based on the total number of words recalled. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | Number of correctly recalled words (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 21.31 | 22.90 | 22.70 | 22.70 |
Verbal Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT via Story Recall. This task is based on the well known Wechsler Memory Scale -Revised Logical Memory task. Participants listened to two brief narratives (stories) and were asked to recall as much as possible immediately after hearing each story and following a 20-minute delay. Assessment was based on number of correctly recalled pieces of information after a delay. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | number of correctly recalled data points (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 35.06 | 37.86 | 39.38 | 41.16 |
Visual Working Memory was assessed at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. This task is based on the Subject Ordered Pointing Task (SOPT). The participant is shown a grid array of 10, 12 or 16 abstract designs and they must choose a new design with each refresh of the screen. Assessment is based on total number of errors. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | total number of errors (Mean) | |||
|---|---|---|---|---|
| Baseline | Score at Month 3 | Score at Month 9 | Score at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 13.22 | 15.66 | 12.35 | 14.00 |
Testosterone was measured at baseline, and at Month 3, Month 9, and Month 12 after the start of the first cycle of ADT. (NCT00223665)
Timeframe: Baseline, Month 3, Month 9, and Month 12
| Intervention | ng/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Measurement at Month 3 | Measurement at Month 9 | Measurement at Month 12 | |
| Intermittent Androgen Suppression (IAS) | 406 | 0.28 | 0.20 | 2.45 |
1 review available for flutamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineopla | 2014 |
4 trials available for flutamide and Androgen-Independent Prostatic Cancer
19 other studies available for flutamide and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferatio | 2020 |
Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.
Topics: Androgen Antagonists; Androgens; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Nitrile | 2022 |
Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
Topics: Androgen Antagonists; Androgens; Cell Line; Flutamide; Humans; Male; Prostate-Specific Antigen; Pros | 2022 |
Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
Topics: Androgen Antagonists; Androgens; Cell Line; Flutamide; Humans; Male; Prostate-Specific Antigen; Pros | 2022 |
Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
Topics: Androgen Antagonists; Androgens; Cell Line; Flutamide; Humans; Male; Prostate-Specific Antigen; Pros | 2022 |
Lncap-AI prostate cancer cell line establishment by Flutamide and androgen-free environment to promote cell adherent.
Topics: Androgen Antagonists; Androgens; Cell Line; Flutamide; Humans; Male; Prostate-Specific Antigen; Pros | 2022 |
Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chlormadinone Acetate; Flut | 2020 |
Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplasti | 2020 |
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostat | 2019 |
Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
Topics: Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Cell Proliferation; Coumarins; Flutamide | 2020 |
Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism.
Topics: Cell Line, Tumor; Cell Proliferation; Choline; Flutamide; Humans; Male; Paclitaxel; Phospholipids; P | 2017 |
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Surv | 2018 |
MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
Topics: Apoptosis; Cell Line, Tumor; Cyclin G1; Flutamide; G1 Phase; Gene Expression Regulation, Neoplastic; | 2018 |
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Benzamides; Disease Progressio | 2019 |
Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemothe | 2019 |
Enzalutamide shows strong activity in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinica | 2014 |
KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Flow | 2014 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic C | 2015 |
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Flutamide; G | 2015 |
Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence.
Topics: Age Factors; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Blood Vessels; Disease Pro | 2015 |
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Topics: Androgen Receptor Antagonists; Anilides; Benzamides; DNA; Drug Resistance, Neoplasm; Flutamide; High | 2016 |
High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Topics: Androgen Antagonists; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Ch | 2016 |